Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003088 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Breast Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,005
- Enrollment target
NCT00003088 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 2,005 participants.
The verdict
NCT00003088, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,005 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at different times or combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy consisting of either doxorubicin, cyclophosphamide, or paclitaxel given at different times with that of combination chemotherapy consisting of doxorubicin plus cyclophosphamide followed by paclitaxel in treating women with stage II or stage IIIA breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG paclitaxel
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,005 participants |
| Start Date | 1997-09 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003088
The ClinicalTrials.gov registry entry for NCT00003088 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,005 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cyclophosphamide is the first listed.
NCT00003088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003088 about?
NCT00003088 is a clinical study titled "Combination Chemotherapy in Treating Patients With Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at different times or combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for breast cancer. PURP...
What is the current status of trial NCT00003088?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,005 participants. The study started on 1997-09. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00003088?
The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003088?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.